Verenium Corporation was a San Diego, California-based industrial biotechnology company founded in 2007 as the result of a merger between Diversa and Celunol. The company specialized in research and development for the production of high performance enzymes used in industrial applications, including biofuel generation, hydraulic fracturing. Verenium was acquired by BASF corporation in 2013. The company's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries including the global food and fuel markets.
Human Genome Sciences (HGS) was a biopharmaceutical corporation founded in 1992 by Craig Venter, Alan Walton and Wally Steinberg. It uses the human DNA sequence to develop protein and antibody drugs. It had drugs under development to treat such diseases as hepatitis C, systemic lupus erythmatosis, anthrax, and cancer. It collaborated with other biotechnology and pharmaceutical companies for development partnerships and licensing.
CD33 or Siglec-3 is a transmembrane receptor expressed on cells of myeloid lineage. It is usually considered myeloid-specific, but it can also be found on some lymphoid cells.
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. Genmab is based in Copenhagen. Internationally, it operates through the subsidiaries Genmab BV in Utrecht, The Netherlands, and Genmab, Inc in Princeton, New Jersey, USA. The Company is publicly traded on the Copenhagen Stock Exchange.
MorphoSys AG is a therapeutic antibody company based in Martinsried, Germany. The company claims to have more than 100 drugs in its wider pipeline, being investigated for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also maintains an internal pipeline with antibodies in preclinical and clinical development.
Cambridge Antibody Technology was a biotechnology company headquartered in Cambridge, England, United Kingdom. Its core focus was on antibody therapeutics, primarily using Phage Display and Ribosome Display technology.
Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. As of 2019, some 56 pharmaceutical companies were developing ADCs.
Stratagene California is an American biotechnological company based in La Jolla, California. It was established in 1984 and incorporated in California. It has been involved with the fields of cellular analysis, cloning, cytogenomics, DNA methylation and DNA Sizing and Quantification and food testing. In 2007, Agilent_Technologies acquired Stratagene, spinning off certain business assets and licensing certain molecular diagnostics technology to a new entity, Decisive_Diagnostics. As of October 2011, the Chief Executive of the new company is Joseph Sorge, original founder and CEO of Stratagene.
James Kuo is founder, CEO and Chairman of the Board of Salt Lake City-based BioMicro Systems, a company that makes research tools that control fluids by using hydrophilic (water-attracting) and hydrophobic (water-repelling) materials instead disruptive mechanical or electrical components.
Life Sciences Foundation (LSF) was a San Francisco-based nonprofit organization that was established in 2011 to collect, preserve, interpret, and promote the history of biotechnology. LSF conducted historical research, maintained archives and published historically relevant materials and information. Their public support of climate-science denier Rep. Dana Rohrabacher in 2018 caused a backlash against the foundation and eroded their scientific credibility.
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big pharmas such as Novaris AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010 decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.
Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug Conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
Sutro Biopharma, Inc. is a public biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. The current CEO, William Newell, joined Sutro in January 2009.
ImmunoGen, Inc. is a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.
Rinat Neuroscience Corporation was a privately held biotechnology company that discovered and developed antibody-based drugs including:
Allergan plc is an Irish-domiciled pharmaceutical company that acquires, develops, and markets brand name drugs, and in 2017 generated 80% net sales from the U.S. healthcare system. Allergan plc was formed in February 2015 when Irish–registered Actavis plc acquired U.S.–registered Allergan, Inc., and assumed the Allergan name. Actavis was a 2013 U.S. tax inversion that moved its legal domicile to Ireland to avoid U.S. taxes. Actavis used the Irish low-tax corporate system to acquire large U.S. pharmaceutical firms, and redomicile them to Ireland.
Synaffix is a biotechnology company headquartered in the Netherlands that has developed a clinical-stage platform technology for antibody-drug conjugates (ADCs) which are used primarily in the treatment of cancer. ADCs utilize potent small molecule payloads, similar to those used for chemotherapy, but are designed to target only the cancer cells and spare normal, healthy tissues.
Array BioPharma is a U.S.-based, clinical stage, pharmaceutical company. The company is a subsidiary of Pfizer.
BenevolentAI is a UK-based artificial intelligence company. They operate under the mission to change the way medicine is designed, developed, tested, and delivered to the market using computational medicine and AI technology. It is a fully integrated AI company with pharmaceutical discovery and clinical development capabilities.
AgeX Therapeutics (“AgeX”) is an American biotechnology company developing medical therapeutics related to human longevity. It was founded in 2017 by Michael D. West, PhD initially as a subsidiary of BioTime, Inc. with backing from British billionaire investor Jim Mellon and others.
